Stock Detail
REPROS THERAPEUTICS INC
Biotechnology
RPRX @ Yahoo Finance | RPRX Option @ Yahoo Finance
Last Day's Data
| Current Price | High | Value Change | Percent Change | Dividend | Previous Close |
|---|---|---|---|---|---|
| $4.77 | $4.79 | $-0.03 | -0.63% | 0.00 | $4.80 |
| Opening Price | Low | Volume | Market Cap | Average Volume | P/E |
| $4.70 | $4.70 | 8,346 | 58.76M | 45,441.5 | -5.02 |
Pivot Table
| R2 | R1 | Pivot | S1 | S2 |
| 4.84 | 4.80 | 4.75 | 4.71 | 4.66 |
Stock Profile
Repros Therapeutics, Inc., a development stage biopharmaceutical company, focuses on the development of drugs to treat hormonal and reproductive system disorders. The company's lead compound includes Proellex, a Phase II clinical trial product, for the treatment of uterine fibroids and endometriosis; and Androxal, a Phase III clinical trial product, which causes increased testosterone secretion from the testes, for the treatment of testosterone deficiency in men resulting from secondary hypogonadism. It also offers phentolamine-based products, such as VASOMAX for the treatment of male erectile dysfunction under the brand name, Z-Max, as well as Bimexes, an oral therapy for men with mild to moderate impotence, and ERxin, an injectable therapy for the treatment of severe erectile dysfunction. The company, formerly known as Zonagen, Inc., was founded in 1987 and changed its name to Repros Therapeutics, Inc. in 2006. Repros Therapeutics is based in The Woodlands, Texas.